Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma

Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits its clinical significance for treating patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyazaki, Katsuki, Morine, Yuji, Xu, Caiming, Nakasu, Chiharu, Wada, Yuma, Teraoku, Hiroki, Yamada, Shinichiro, Saito, Yu, Ikemoto, Tetsuya, Shimada, Mitsuo, Goel, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954241/
https://www.ncbi.nlm.nih.gov/pubmed/36831279
http://dx.doi.org/10.3390/cells12040612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954241/
https://www.ncbi.nlm.nih.gov/pubmed/36831279
http://dx.doi.org/10.3390/cells12040612

Ejemplares similares